Defining a Lineage-specific Chimerism Threshold for the Use of Donor Lymphocyte Infusions in Treating Myeloid Malignancies

Overview

Journal Bone Marrow Transplant

Date 2025 Jan 13

PMID 39806028

Authors

Christian J Puzo

Stuart Seropian

Henry Rinder

Christopher A Tormey

Alexa J Siddon

Affiliations

Soon will be listed here.

References

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

Abou Dalle I, Atoui A, Bazarbachi A . The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation. Front Oncol. 2022; 11:793274. PMC: 8761806. DOI: 10.3389/fonc.2021.793274. View

Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D . Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017; 35(11):1154-1161. PMC: 5455603. DOI: 10.1200/JCO.2016.70.7091. View

Koreth J, Kim H, Nikiforow S, Milford E, Armand P, Cutler C . Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014; 20(10):1516-21. PMC: 4477288. DOI: 10.1016/j.bbmt.2014.05.025. View

Lee H, Saliba R, Rondon G, Chen J, Charafeddine Y, Medeiros L . Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015; 21(11):1948-54. PMC: 4604040. DOI: 10.1016/j.bbmt.2015.07.005. View

Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S . Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant. 2008; 14(10):1148-1155. DOI: 10.1016/j.bbmt.2008.07.013. View

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garcon L . Utility of assessing CD3 cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia. HLA. 2022; 100(1):18-23. PMC: 9303291. DOI: 10.1111/tan.14557. View

Hoffmann J, Stabla K, Burchert A, Volkmann T, Bornhauser M, Thiede C . Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. Ann Hematol. 2013; 93(2):279-85. DOI: 10.1007/s00277-013-1961-4. View

10.

Azam F, Latif M, Farooq A, Tirmazy S, Alshahrani S, Bashir S . Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Rep Oncol. 2019; 12(3):728-736. PMC: 6792426. DOI: 10.1159/000503095. View